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ABSTRACT
Background: Delayed gastric emptying may impair
L-dopa absorption, contributing to motor fluctuations. We
evaluated the effect of camicinal (GSK962040), a gastropro-
kinetic, on the absorption of L-dopa and symptomsof PD.
Methods: Phase II, double-blind, placebo-controlled
trial. Participants were randomized to receive camicinal
50mg once-daily (n5 38) or placebo (n5 20) for 7 to 9
days.
Results: L-dopa exposure was similar with coadminis-
tration of camicinal compared to placebo. Median time
to maximum L-dopa concentration was reduced, indi-
cating more rapid absorption of L-dopa. Camicinal
resulted in significant reduction in OFF time (–2.31
hours; 95% confidence interval: –3.71, –0.90), signifi-
cant increase in ON time (11.88 hours; 95% confi-
dence interval: 0.28, 3.48) per day, and significant
decrease in mean total MDS-UPDRS score (–12.5;
95% confidence interval: –19.67, -5.29). Camicinal
treatment was generally well tolerated.
Conclusions: PD symptom improvement with camici-
nal occurred in parallel with more rapid absorption of
L-dopa. This study provides evidence of an improve-
ment of the motor response to L-dopa in people with
PD treated with camicinal 50mg once-daily compared
with placebo, which will require further evaluation.
VC 2017 The Authors. Movement Disorders published
by Wiley Periodicals, Inc. on behalf of International
Parkinson and Movement Disorder Society.
Key Words: Parkinson’s disease/parkinsonism; Clinical
trials Randomized controlled (CONSORT agreement)
Delayed gastric emptying (GE) affects more than
70% of PD patients.1,2 Levodopa is rapidly absorbed
in the proximal small bowel. If GE is delayed, the
absorption of L-dopa is impaired and may result in
delayed ON and motor fluctuations.3,4 Gastroproki-
netics may enhance GE, L-dopa absorption, and motor
function.5-8 Camicinal is a motilin receptor agonist,
which enhances GE in healthy volunteers and patients
with diabetic gastroparesis.9,10
The primary outcome of this study was to evaluate
the effect of camicinal on L-dopa pharmacokinetics
(PK) in patients with PD. We hypothesized that
camicinal would improve GE resulting in increased
L-dopa absorption, earlier L-dopa peak concentrations,
increased drug exposure, and better control of motor
and nonmotor symptoms.11 We also evaluated the
safety of camicinal in PD.
Materials and Methods
This was a multicenter (11), international (UK, Europe,
Australia) phase II randomized, double-blind, placebo-
controlled study. It was conducted in accordance with
the Declaration of Helsinki and registered on www.
clinicaltrials.gov (NCT01602549). Eligible patients were
randomized 2:1 to receive camicinal (50 mg once-daily) or
placebo.
There was a screening period of 1 to 21 days, a
7- to 9-day treatment period, and a 14-day follow-up
period.
The primary outcome of the study was change in
L-dopa pharmacokinetics. Secondary outcomes included
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change in GE, motor, and nonmotor symptoms. Camici-
nal safety and tolerability were also evaluated.
Initially this was a dose-ranging study where partici-
pants were to receive camicinal 25, 50, or 125 mg.
However, after an interim review and concerns about
the development potential of the 125-mg dose, the
protocol was amended to compare a single strength of
camicinal (50 mg) with placebo. One patient received
camicinal 125 mg before this amendment and is
included in the adverse events (AEs) summary.
Patients (40-80 years old) diagnosed with idiopathic
PD according to the UK Brain Bank Criteria (modified
H & Y stage II-IV) with suboptimal motor control on
L-dopa-based treatment were eligible. Motor fluctua-
tions were defined as wearing-off, peak-dose dyskine-
sias, and delayed or absent ON periods that impacted
functional status or quality of life. Incapacitating
peak-dose or biphasic dyskinesias were an exclusion
criterion. Patients were required to have a stable
L-dopa therapy regimen for at least 4 weeks preceding
screening, and therapies were not altered during the
study period. Patients were suitable for participation if
their GE T1/2 at screening was70 minutes, as deter-
mined by the 13C-Gastric Emptying Breath Test
(GEBT; Cairn Diagnostics, Brentwood, TN). Signifi-
cant gastric pathology or surgery or use of medica-
tions influencing upper gastrointestinal motility within
a week of study participation were exclusion criteria.
Patients attended 5 visits: screening, first dosing (day 1),
mid-point review (day 461), final dosing (day 861),
and follow-up (day 146 2 after final dose).
At the screening, first, and final dosing visits, patients
attended in the morning, fasted and in a functionally
defined OFF state. Patients took their usual L-dopa-
based medication (time 0) after the study medication
(time -90 minutes). They received a standardized
GEBT test meal (time -10 minutes) and did not ingest
any additional food for the 240-minute study period.
Plasma samples were obtained at predetermined time
points for L-dopa pharmacokinetics analysis; area under
the concentration-time curve (AUC), maximal concentra-
tion (Cmax), and time to Cmax (Tmax) were calculated.
The full MDS-UPDRS was assessed at baseline and
days 1 and 8, just before L-dopa dosing. The MDS-
UPDRS Part III was assessed by blinded raters at 120,
180, and 240 minutes after dosing. Subjects completed
a daily motor symptoms diary. AEs were assessed
using a symptom diary.
Statistical Analysis
Analyses were performed on the “All Subjects” pop-
ulation: participants who received at least one dose of
study medication.
The planned sample size was calculated using data
from Hauser and colleagues.13 Assuming the mean
(standard deviation) of dose-normalized L-dopa AUC0-
4 to be 48.65 (18.93) ng.h/mL/mg, corresponding to a
coefficient of variation of 38.9%, the planned sample
size of 45 subjects (camicinal 30, placebo 15) was
powered (90% power, 5% alpha) to detect a 1.5-fold
change in mean AUC0-4.
An interim analysis was performed after 16 completed
subjects to assess futility and re-estimate sample size. At
the interim analysis, the probability that the camicinal to
placebo fold change in L-dopa AUC0-4 was calculated. If
this probability was greater than 70%, the study would
stop. Futility criteria were not met. The sample size was
increased to 58. Additional assessments were included in
a revised protocol (“ON”/”OFF” symptoms at the
screening visit to allow for baseline comparisons and
MDS-UPDRS 3 assessments for evaluation of motor
symptoms at the subject defined “ON” time).
Pharmacokinetic Analysis
Pharmacokinetic parameters were calculated by
noncompartmental methods using Phoenix WinNonlin
(v. 6.2; Certara) for baseline and days 1 and 8. L-dopa
exposure parameters (AUC0-t, Cmax) were dose-
normalized by dividing the parameter value by the
equivalent L-dopa dose in mg based on each subject’s
individual L-dopa-based regimen. These parameters
were log-transformed and analyzed using a mixed-
model analysis of variance (ANOVA), from which
point estimates and 95% confidence intervals (CIs) for
the ratio, “camicinal 50 mg: Placebo” were calculated.
Change from baseline to day 8 in L-dopa Tmax was
analyzed using a Wilcoxon rank-sum test.
Efficacy Analysis
An estimation approach was used for all efficacy end-
points. The point estimate and corresponding 95% CI
for the difference “camicinal - Placebo” were con-
structed, using the residual error from the model fitted.
Change from baseline GE T1/2 and changes from
baseline in MDS-UPDRS were analyzed by a mixed-
model ANOVA.
For the purpose of statistical analysis, diary categories
of ON without dyskinesia and ON with nontrouble-
some dyskinesia were combined to a single category
referred to as “ON.” The change from baseline in
awake hours spent ON and OFF was analyzed sepa-
rately using an analysis of covariance (ANCOVA) model
with the baseline measurement included as a covariate.
Results
Twenty patients were randomized to placebo and 38
to camicinal. One subject from the placebo group
withdrew consent. One patient receiving camicinal
was withdrawn because of noncompliance. Baseline
demographics and disease characteristics of the groups
were comparable.
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There was no significant difference in L-dopa AUC
(0-t) or Cmax when camicinal was coadministered on
days 1 or 8. However, the Tmax occurred approxi-
mately 23 minutes sooner on day 8 with camicinal
versus placebo. Median Tmax on day 8 was reduced
from 120 minutes (range, 18-240) at baseline to 97
minutes (18-240) in the camicinal group compared to
placebo, where Tmax increased from 90 (18-216) to
120 minutes (30-210; P50.186).
GE T1/2 was reduced by 5.3 minutes (95% CI: -6.9,
17.6) in the camicinal group compared to placebo
from baseline to day 8.
Compared to placebo, treatment with camicinal
resulted in a significant improvement from baseline of
approximately 13 points (95% CI: 5, 20) in the total
MDS-UPDRS scores. MDS-UPDRS subsection scores
improved from baseline to day 8 in the camicinal group
versus placebo; part I (4 points; 95% CI: 2, 5), part II
(2 points; 95% CI: 0, 5), and part III (5 points, 95% CI:
0, 10). On day 8, at 4 hours postdose, the mean
MDS-UPDRS part III score was 9 points (95% CI: 3, 15)
lower for the camicinal group than the placebo group.
Camicinal resulted in a significant increase in the
number of hours/day spent in the ON state (11.88
hours; 95% CI: 0.28, 3.48) and a significant reduction
in time spent in the OFF state (–2.31 hours; 95% CI:
–3.71, –0.90) compared to placebo (Table 1).
There was a correlation between reduction in
L-dopa Tmax and improvements in OFF time
(r5 0.31; P< 0.05; Fig. 1). Regression of change
from baseline in Tmax against change in OFF time
estimates that, on average, a 1-hour reduction in
Tmax led to a 50-minute reduction in OFF time.
A similar correlation was observed between a reduc-
tion in Tmax and an increase in ON time.
Overall, camicinal pharmacokinetics were similar to
those observed in previously in healthy volunteers and
diabetic subjects with gastroparesis.9,10
Reported AEs were similar in both groups, the most
frequent being headache and fatigue. Two subjects
receiving camicinal reported nonfatal serious adverse
events: pruritus and circulatory collapse (not related
to camicinal).
Discussion
Although there was similar L-dopa drug exposure
between the two groups, the median L-dopa Tmax in
the camicinal group occurred, on average, 60 minutes
earlier than in the placebo group. This suggests that
although camicinal co administration did not increase
overall L-dopa exposure, it did result in more rapid
time to maximal plasma concentration. However,
the precision of the Tmax and Cmax estimates may be
low given that the L-dopa plasma concentrations
were assessed only every 30 minutes. This could be
further explored in the future with more frequent PK
sampling.
Patients who received camicinal reported less OFF
and more ON time compared to those receiving pla-
cebo, a statistically significant improvement which
may also be clinically significant.14 Reduction in OFF
time was greater than might have been predicted from
the modest change in GE, possibly reflecting the het-
erogeneity of gastric motility, disease progression, or
potentially another pharmacological mechanism.
Significant improvements in MDS-UPDRS scores
were observed in patients who received camicinal,
most likely explained by the decrease in L-dopa Tmax.
TABLE 1. Change from baseline to end of treatment period in number of hours spent daily in each symptoms state
Adjusted Mean (95% CI)
State Placebo (n517) Camicinal 50mg (n5 36)
Adjusted Mean Difference:
Camicinal 50mg - placebo (95% CI)
OFF 0.99 (–0.17, 2.14) 21.32 (22.11, 20.53) 22.31 (23.71, 20.90)
ON 20.82 (22.13, 0.50) 1.06 (0.15, 1.96) 1.88 (0.28, 3.48)
ON without dyskinesia 20.37 (22.12, 1.37) 0.73 (20.47, 1.93 1.11 (21.01, 3.22)
ON with nontroublesome dyskinesia 20.47 (21.52, 0.59) 0.34 (20.39, 1.06) 0.80 (20.48, 2.09)
ON with troublesome dyskinesia 20.12 (20.38, 0.15) 0.20 (0.02, 0.39) 0.32 (20.01, 0.64)
The adjusted means and differences were estimated using an ANCOVA model fitting treatment and baseline amount of hours spent daily in ON/OFF state as
main effects.
FIG. 1. Correlation between change from baseline in OFF time and
levodopa Tmax on day 8.
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Tolerability of camicinal 50 mg once-daily for 7 to 9
days was similar to placebo. Two AEs of dyskinesia
occurred in the camicinal group, an effect that could
be expected to occur from a more rapid drug absorp-
tion (shorter time to Tmax).
Although we found a trend toward more rapid GE
in the camicinal group, this was not statistically signif-
icant. GE assessed by GEBT over a 4-hour period may
not be of sufficient sensitivity to distinguish subtle
changes in emptying rates.
Limitations of this study include inability to pre-
cisely assess Tmax or to accurately determine “time to
ON” attributed to sampling frequency and study
design. Thus, the mechanism(s) by which camicinal
leads to motor improvement remains uncertain. With
the relatively small sample size and short duration of
treatment, it was not possible to determine whether
the observed benefits were a true drug effect.
This is the first report that the motilin receptor
agonist camicinal may improve the motor response
to L-dopa in PD with motor fluctuations. Camicinal
may improve motor fluctuations by shortening the
time to peak L-dopa plasma concentration. Camici-
nal represents a promising adjunctive therapeutic
option worthy of further evaluation in a larger
study.
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